51
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Clearside Biomedical, Inc. (NASDAQ: CLSD) Reports Positive Safety Results”
Clearside Biomedical, Inc. (NASDAQ: CLSD) a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, reported Tuesday positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD). Clearside Biomedical stock price surged about 40% during Tuesday early trading session. The primary endpoints were achieved in Cohort 1, as the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug related treatment emergent adverse eve
ReViral Ltd : ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Clearside Biomedical Reports Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
E-Mail
New research results for patients with breast and HPV-associated throat cancers are the highlights among 23 presentations by ECOG-ACRIN Cancer Research Group researchers at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, occurring virtually June 4-8. The National Cancer Institute (NCI), part of the National Institutes of Health, funded these studies.
Breast Cancer
Platinum chemotherapy fails in phase III trial for triple-negative breast cancer, basal-like subtype
Abstract 605: About 80% of triple-negative breast cancers (TNBC) are a subtype called basal-like. Typically, patients with TNBC receive chemotherapy before surgery to shrink the tumor(s). The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will progress after surgery. A previous clinical trial demonstrated that additional capecitabine chemotherapy after surgery helps decrease the chance of recurrence. Yet, although capecitabine he